Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
Status:
Recruiting
Trial end date:
2023-03-18
Target enrollment:
Participant gender:
Summary
In this prospective study, 30 newly untreated elderly patients with acute myeloid
leukemia(AML) who were not suitable for standard chemotherapy were enrolled to observe the
efficacy and side effects of venetoclax (VEN) combined with azacytidine (AZA) and
chemotherapy in newly treated elderly patients with AML. Overall survival (OS), complete
remission rate/complete remission with incomplete recovery of blood cell count (CR/ CRi) were
used as the primary endpoints, and time to response (TTR), duration of response (DOR),
mortality, and recurrence rate were used as secondary endpoints,and the incidence of adverse
events were evaluated.